Innovation Kyoto 2021 Investment Limited Partnership ("KYOTO-iCAP No.2 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as general partner, has made an additional investment in Eurus (headquartered in Fujisawa City, Kanagawa Prefecture; Takato Noumi, Representative Director), has made an additional investment in Eurus Therapeutics K.K. (headquartered in Fujisawa City, Kanagawa Prefecture; Takato Noumi, Representative Director).

Outline of this investment
Eurus Therapeutics is a biotech venture founded in February 2021 based on an idea for a new gene therapy, a novel genome editing technology that does not use the CRISPR/Cas system, and a new drug discovery platform that can provide unprecedented therapeutic strategies. We aim to establish a business. We are developing the technology and promoting the business by utilizing the technology and knowledge of national universities and other institutions.

New technologies for gene therapy have been applied to various genetic diseases since the discovery of the CRISPR/Cas system. On the other hand, the use of CRISPR/Cas systems still involves a number of technical and therapeutic application issues, and from a business perspective, licensing agreements must be concluded with U.S. research institutions. In addition, there have been a number of cases, both domestic and international, where companies with proprietary technologies have formed large alliances prior to entering clinical trials, making this an area that is attracting considerable attention.

While testing various novel concepts, Eurus Therapeutics has established a method that can induce simple and precise genome editing without the use of exogenous proteins such as Cas. This technology is expected to solve the problems faced by the CRISPR/Cas system. Kyoto iCAP highly evaluated Eurus Therapeutics' technology as having the potential to bring significant change to the global genome editing market, and has therefore made an additional investment of 75 million yen. The total amount raised is 150 million yen, and in addition to Kyoto iCAP, the other investors include an investment limited partnership managed by Nissay Capital Corporation. with this procurement, Eurus Therapeutics aims to improve the level of its technology and complete demonstration experiments aimed at treating diseases.

Overview of Eurus Therapeutics, Inc.
Established February 2021
Business Development of novel gene therapies
Head Office Fujisawa City, Kanagawa Prefecture
Representative Director: Takahito Nohmi